Skip to main content
Zelluna ASA logo

Zelluna ASA — Investor Relations & Filings

Ticker · ULTI ISIN · NO0010851603 LEI · 254900B4VALJZR9TL744 OL Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2020-04-02 Remuneration Information
Country NO Norway
Listing OL ULTI

About Zelluna ASA

https://www.zelluna.com/

Zelluna ASA is a cell therapy company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company's proprietary TCR-NK platform is designed to combine the high-precision targeting of TCRs with the potent, innate anti-tumor activity of NK cells. This approach aims to overcome the challenges associated with treating solid tumors. Zelluna is focused on creating a new generation of allogeneic, "off-the-shelf" cell therapies. The mission is to deliver transformative and potentially curative treatments for patients with advanced solid cancers, addressing a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Ultimovacs ASA – Notice of Annual General Meeting on 23 April 2020
Remuneration Information Classification · 98% confidence The document is explicitly titled "The Board of Directors' statement on remuneration" and discusses the guidelines for salaries, bonuses, pensions, and share options for senior executives ('Management'). It references presentation for approval by the General Meeting and confirms adherence to guidelines for the previous financial year (2019). This content directly aligns with the definition of a Remuneration Information document, which corresponds to the DEF 14A filing type in the provided schema, often related to proxy statements or compensation reports.
2020-04-02 English
Ultimovacs ASA – Notice of Annual General Meeting on 23 April 2020
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2019' and contains comprehensive sections including a CEO statement, Directors' report, corporate governance, and financial statements for the Ultimovacs Group. It is a full-length annual report covering the company's activities, financial performance, and strategic outlook for the 2019 fiscal year. FY 2019
2020-04-02 English
Ultimovacs ASA – Notice of Annual General Meeting on 23 April 2020
AGM Information Classification · 100% confidence The document is explicitly titled "Notice of Annual General Meeting" and contains details about the date, time, and location of the meeting (23. April 2020). It includes sections for shareholders to register attendance and grant proxies, complete with voting instructions for specific agenda items (e.g., approval of accounts, election of directors, remuneration). This content directly relates to the preparation and execution of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R).
2020-04-02 English
Ultimovacs ASA – Notice of Annual General Meeting on 23 April 2020
AGM Information Classification · 100% confidence The document text is explicitly titled 'INNKALLING TIL ORDINÆR GENERALFORSAMLING I ULTIMOVACS ASA' (NOTICE OF ANNUAL GENERAL MEETING IN ULTIMOVACS ASA). The agenda items confirm this, including 'ELECTION OF CHAIR OF THE MEETING', 'APPROVAL OF THE ANNUAL ACCOUNTS AND ANNUAL REPORT', and 'ELECTION OF THE BOARD OF DIRECTORS'. This content directly corresponds to the materials presented or distributed for an Annual General Meeting. Therefore, the correct classification is AGM-R.
2020-04-02 English
Ultimovacs ASA – Notice of Annual General Meeting on 23 April 2020
AGM Information Classification · 98% confidence The document explicitly states it is a 'Notice of Annual General Meeting' for Ultimovacs ASA, scheduled for 23 April 2020. This directly relates to the Annual General Meeting (AGM). Although it is a notice, the content is specific to the AGM proceedings and materials, making 'AGM-R' (AGM Information) the most appropriate classification, as it contains the notice and context for the meeting itself, rather than just announcing the publication of a separate report (which would be RPA/RNS). The length is short, but the content is the core notice of the meeting.
2020-04-02 English
Ultimovacs ASA – Annual Report 2019
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2019' and contains comprehensive sections including a CEO statement, Directors' report, corporate governance, and financial statements for the Ultimovacs Group. It is a full-length annual report covering the company's activities, financial performance, and strategic outlook for the 2019 fiscal year. FY 2019
2020-04-01 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.